

9th April 2020

Dear Healthcare Professional,

As the COVID-19 pandemic continues to evolve, we wanted to reassure you of the steps we are taking to ensure the health and safety of our workforce and the continuity of our operations across the Seqirus global network.

We continue to follow the latest advice from relevant authorities to guide the implementation of safety measures for our staff, including strict hygiene and cleaning protocols, remote working arrangements, and travel and group meeting bans.

We have enacted our business continuity plans across our global network to minimise disruption to the manufacture and on-time supply of our influenza vaccines, medicines, vaccines and Products of National Significance and are closely tracking any potential impacts to our operations. We are also working with our international partners to ensure continued supply of our in-licensed medications and vaccines to patients in Australia.

In this environment, there has been increased demand at the patient and pharmacy level for Acarizax & Grazax. At this point in time there is sufficient inventory and we do not anticipate constraint on supply. If there is difficulty with supply, please ask your pharmacist to contact their wholesaler.

We will continue to provide regular updates to the community should there be a change in the situation with respect to supply. Please see our [corporate website](#) for more about our COVID-19 response.

Regards

NATASHA HUTCHISON
Business Unit Director